Inspection prep notes · Quality system
Product quality review (annual review)
Also called: product quality review, annual product review, PQR, APR
FDA looks less at whether an annual review report exists than at whether the review is done on time for every product and whether the problems it identifies lead to action. The findings below are quoted from warning letters and FDA 483s.
What inspectors cited
1Annual product reviews were not performed for the drug products made
You have not performed an annual product review (APR) of your OTC drug products manufactured since 2022.
FDA Warning Letter · Sklar Personal Care Inc. · 2025-12-16 · View document
Your firm issued SOP 6.34 rev 00 Annual Product Review Procedure on 05/30/2025 but has not conducted annual product reviews for 16 of the [redacted] drug products compounded at your facility for calendar year 2025.
FDA 483 · LeeSar Inc · 2026-11-05 · View document
2Annual product reviews were not approved on time
All APR reports due in 2025 were approved after the dates required by the procedure.
FDA 483 · Right Value Drug Stores LLC · 2026-09-30 · View document
Annual product reviews for BPU, Alyx, Amicus, and Intersol products for the calendar year 2023 were significantly delayed until being signed and approved on 12 SEP 2024.
FDA 483 · Fenwal International, Inc. · 2026-10-30 · View document
3No procedure for annual product review was established
Your QU also failed to perform annual product reviews of your drug products since our previous inspection in 2018. Furthermore, no written procedures for this requirement were available (21 CFR 211.180(e)).
FDA Warning Letter · GC America, Inc. · 2026-05-26
Your firm failed to conduct annual product reviews of medical gas being filled and distributed at your facility and failed to establish an SOP for annual product review management.
FDA 483 · Conroe Welding Supply, Inc · 2026-10-23 · View document
4The annual review did not include complaints, investigations or component data
Your quality unit failed to review all complaints and investigations related to finished drug products when conducting annual reviews.
FDA 483 · Jacobus Pharmaceutical Company, Inc. · 2024-01-17 · View document
For example APRs do not include defect rates, testing summaries, or supplier qualification status.
FDA 483 · Fenwal International, Inc. · 2026-10-30 · View document
5No corrective and preventive action was initiated for trends identified in the annual review
Specifically, Your firm’s own Product Quality Reviews (PQRs) for 2024 and 2025 identified that the root cause category of “Methods” accounted for approximately 41% and 40%, respectively, of critical/major/significant deviations in each review period. Despite this recurring trend being formally documented in two [redacted] reviews, the Quality Unit has not initiated a Corrective and Preventive Action (CAPA) to systemically address this issue.
FDA 483 · Protein Sciences Corporation · 2026-10-26 · View document
Specifically, In your Annual Product Reviews for the following products you identify trends but fail to initiate appropriate corrective and preventive actions to address and correct these failures.
FDA 483 · Hospira Inc. A Pfizer Company · 2021-04-21 · View document
Questions to check against your procedures
- Do you perform an annual review every year for every drug product you make?
- Is there a written procedure for the annual review?
- Are annual review reports approved by the due dates set in your procedure?
- Does the annual review cover all complaints and investigations related to the product?
- Does the annual review include component defect rates, testing summaries and supplier qualification status?
- Do you initiate corrective and preventive action for trends identified in the annual review?
Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-16.